Moody National Bank Trust Division Makes New $249,000 Investment in Boston Scientific Co. (NYSE:BSX)

Moody National Bank Trust Division bought a new stake in Boston Scientific Co. (NYSE:BSX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 2,786 shares of the medical equipment provider's stock, valued at approximately $249,000.

A number of other hedge funds have also made changes to their positions in BSX. Values First Advisors Inc. acquired a new stake in Boston Scientific during the third quarter valued at $28,000. Dunhill Financial LLC lifted its holdings in shares of Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 152 shares during the last quarter. Global Wealth Strategies & Associates grew its stake in shares of Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 250 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. acquired a new position in Boston Scientific in the third quarter worth approximately $30,000. Finally, Capital Performance Advisors LLP bought a new position in Boston Scientific during the third quarter valued at approximately $30,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded up $1.26 during trading on Thursday, hitting $98.15. 5,020,057 shares of the stock were exchanged, compared to its average volume of 5,327,683. The company has a market capitalization of $144.65 billion, a price-to-earnings ratio of 81.11, a price-to-earnings-growth ratio of 2.48 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. Boston Scientific Co. has a 1-year low of $59.85 and a 1-year high of $98.31. The company's fifty day simple moving average is $90.57 and its 200-day simple moving average is $84.23.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The firm had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same quarter in the previous year, the company earned $0.50 earnings per share. The business's revenue was up 19.3% compared to the same quarter last year. Sell-side analysts expect that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on BSX. Wells Fargo & Company increased their price target on shares of Boston Scientific from $98.00 to $100.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 11th. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a research report on Friday, January 10th. Canaccord Genuity Group boosted their price target on Boston Scientific from $98.00 to $101.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. Royal Bank of Canada increased their price objective on Boston Scientific from $95.00 to $98.00 and gave the company an "outperform" rating in a report on Thursday, October 24th. Finally, Evercore ISI boosted their target price on Boston Scientific from $82.00 to $90.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $97.26.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,119 shares of the company's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the sale, the executive vice president now directly owns 35,319 shares in the company, valued at $3,179,416.38. This represents a 10.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of Boston Scientific stock in a transaction on Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the transaction, the executive vice president now directly owns 978 shares of the company's stock, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 29,989 shares of company stock valued at $2,702,261 over the last quarter. 0.50% of the stock is owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.